Nellcor™ Investigational Device Sitting-Walking Study

Feasibility of the Investigational Nellcor™ Investigational Device During Non-Motion and Walking Motion Conditions in Adult Volunteers

To examine pulse rate and blood oxygen saturation accuracy of the Nellcor™ Investigational Device during non-motion and walking motion conditions in a diverse patient population through non-invasive means

Study Overview

• Status: Not yet recruiting
• Conditions: Oxygen Saturation

• Study Type: Observational
• Enrollment (Estimated): 30

Contacts and Locations

• Study Contact: Name: Ami Stuart; Email: ami.stuart@medtronic.com
• Study Contact Backup: Name: Hannah Bowman; Phone Number: 720-930-1695; Email: Hannah.bowman@medtronic.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Healthy Volunteers

Description

Inclusion Criteria:

• Male or female participants ≥18 years of age, and <75 years of age.
• Participant is able to participate for the duration of the study
• Participant is willing to sign an informed consent form (ICF)
• Participant weighs > 40kg
• Participants must be a non-smoker or not have smoked within 36 hours prior to the study

Exclusion Criteria:

• Participant self-reported prior injury or trauma to fingers or hands, which in the opinion of the investigator, may change blood flow or vascular supply and affect the ability to test sensors
• Physiologic abnormalities that prevent proper application of pulse oximetry sensor
• Severe contact allergies that cause a reaction to standard adhesive materials such as those found in medical sensors and electrodes
• Individuals of childbearing potential who are self-reported as pregnant, or who are self-reported as trying to get pregnant
• Morbid obesity (defined as BMI > 39.5)
• Weight > 136 kg
• Participants who self-report problems of unsteadiness or imbalance issues and/or who are unable to walk on a treadmill without holding onto the handrails
• Participant self-reported known heart or cardiovascular conditions such as:
• Uncontrolled hypertension (Systolic pressure ≥ 140mmHg or Diastolic pressure > 90mmHg on 3 consecutive readings day of screening)
• Heart arrhythmias other than sinus arrhythmia (Self-reported and/or as identified on ECG day of screening).
• History of heart attack, blocked artery, history of myocardial ischemia, angina, myocardial infarction, congestive heart failure, cardiomyopathy, stroke, transient ischemic attack, or carotid artery disease
• Participants with self-reported clotting disorders, such as:
• History of bleeding disorders or personal history of prolonged bleeding from injury
• History of blood clots
• Hemophilia
• Current use of prescription blood thinner
• Participants with other self-reported, known health conditions, such as:
• Diabetes
• Thyroid disease
• Kidney disease / chronic renal impairment
• History of seizures (except childhood febrile seizures), epilepsy, or unexplained syncope
• Recent history of frequent migraine headaches, as determined medically relevant by the PI
• History of head injury, as determined medically relevant by the PI
• Cancer / chemotherapy
• Sickle cell disease
• History of hospital admission or a surgical procedure in the 60 days prior to study enrollment (self-reported)
• Participants with any contraindications to protocol specific repositioning techniques
• Unwillingness or inability to remove colored nail polish from test digit(s)
• Participants who have self-reported health conditions beyond what is captured in the prior exclusion criteria, which in the opinion of the Investigator and/or Clinical Staff would classify the participant as medically unsuitable

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Healthy Volunteers; All subjects who meet the inclusion criteria and none of the exclusion criteria will be enrolled into the test group and will participate in data collection with use of the Nellcor™ Investigational device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Accuracy of the investigational device SpO2 as compared to the reference device SpO2	From enrollment to study exit, 1.5 hours
Accuracy of the investigational device pulse rate as compared to the reference device pulse rate.	From enrollment to study exit, 1.5 hours

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of the time under evaluation that the NellcorTM Investigational Device provides a SpO2 and PR reading	From enrollment to study exit, 1.5 hours

Collaborators and Investigators

• Sponsor: Medtronic - MITG

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: November 14, 2025
• First Submitted That Met QC Criteria: November 14, 2025
• First Posted (Actual): November 18, 2025

Study Record Updates

• Last Update Posted (Actual): May 14, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: MDT25003NPDSWF

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No